Louise A Knight
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Louise A Knight has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Augusta Fernando
Translational Oncology Research Centre, Queen Alexandra Hospital, The Pathology Centre, Portsmouth, PO6 3LY, UK
1 shared publication - Christian M. Kurbacher
Department of Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, 53111 Bonn, Germany
1 shared publication - Ian A. Cree
Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, UK
1 shared publication - Ralf Reichelt
L.a.n.c.e. Inc, Friedensplatz 16, 53111 Bonn, Germany
1 shared publication - Sharon Glaysher
Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth PO6 3LY, UK
1 shared publication Susanne Dexel
L.a.n.c.e. Inc, Friedensplatz 16, 53111 Bonn, Germany
1 shared publication
Latest Publications
- Open Access
- 28 January 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 38
Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay
Previous data suggest that lipophilic statins such as fluvastatin and N-bisphosphonates such as zoledronic acid, both inhibitors of the mevalonate metabolic pathway, have anti-cancer effectsin vitroand in patients. We have examined the effect of fluvastatin alone and in combination with zoledronic acid in the ATP-based tumour chemosensitivity assay (ATP-TCA) for effects on breast and ovarian cancer tumour-derived cells. Both zoledronic acid and fluvastatin showed activity in the ATP-TCA against breast and ovarian cancer, though fluvastatin alone was less active, particularly against breast cancer. The combination of zoledronic acid and fluvastatin was more active than either single agent in the ATP-TCA with some synergy against breast and ovarian cancer tumour-derived cells. Sequential drug experiments showed that pre-treatment of ovarian tumour cells with fluvastatin resulted in decreased sensitivity to zoledronic acid. Addition of mevalonate pathway components with zoledronic acid with or without fluvastatin showed little effect, while mevalonate did reduced inhibition due to fluvastatin. These data suggest that the combination of zoledronic acid and fluvastatin may have activity against breast and ovarian cancer based on direct anti-cancer cell effects. A clinical trial to test this is in preparation.
- 28 January 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 38
Open AccessActivity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay
Previous data suggest that lipophilic statins such as fluvastatin and N-bisphosphonates such as zoledronic acid, both inhibitors of the mevalonate metabolic pathway, have anti-cancer effectsin vitroand in patients. We have examined the effect of fluvastatin alone and in combination with zoledronic acid in the ATP-based tumour chemosensitivity assay (ATP-TCA) for effects on breast and ovarian cancer tumour-derived cells. Both zoledronic acid and fluvastatin showed activity in the ATP-TCA against breast and ovarian cancer, though fluvastatin alone was less active, particularly against breast cancer. The combination of zoledronic acid and fluvastatin was more active than either single agent in the ATP-TCA with some synergy against breast and ovarian cancer tumour-derived cells. Sequential drug experiments showed that pre-treatment of ovarian tumour cells with fluvastatin resulted in decreased sensitivity to zoledronic acid. Addition of mevalonate pathway components with zoledronic acid with or without fluvastatin showed little effect, while mevalonate did reduced inhibition due to fluvastatin. These data suggest that the combination of zoledronic acid and fluvastatin may have activity against breast and ovarian cancer based on direct anti-cancer cell effects. A clinical trial to test this is in preparation.